Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Edwards Lifesciences Corporation
EW·Healthcare
B ★★★Hold
Current$102.14
Target$103.50
Return+1.3%
Nov 7, 2026

Edwards Lifesciences combines a durable TAVR franchise with fast-growing mitral and tricuspid therapies, but demanding cash-flow valuation and competition limit near-term upside despite strong clinical momentum.

Score
73
MGIC Investment Corporation
MTG·Financials
B ★★★Hold
Current$28.60
Target$32.30
Return+12.9%
Nov 7, 2026

MGIC Investment combines profitable mortgage insurance, substantial capital reserves, and aggressive buybacks to compound per-share value, but weakening premium yields and rising mortgage delinquencies constrain upside.

Score
73
CoreCivic, Inc.
CXW·Industrials
B ★★★Hold
Current$28.67
Target$32.25
Return+12.5%
Nov 7, 2026

CoreCivic benefits from rising detention utilization, a stronger balance sheet, and aggressive share repurchases, but government policy dependence and uncertain post-sale contract economics constrain its long-term investment appeal.

Score
73
Kyndryl Holdings, Inc.
KD·Technology
B ★★★Hold
Current$16.29
Target$20.66
Return+26.8%
Nov 7, 2026

Kyndryl offers discounted exposure to an improving enterprise infrastructure-services turnaround, but weak trailing free cash flow, legacy revenue contraction and higher financing costs make sustained cash conversion the decisive investment test.

Score
73
Gulfport Energy Corporation
GPOR·Energy
B ★★★Hold
Current$150.00
Target$184.00
Return+22.7%
Nov 7, 2026

Gulfport Energy offers an attractive cyclical natural gas investment through efficient Appalachian assets, improving liquids production, and significant buybacks, but elevated capital spending and commodity volatility constrain free cash flow.

Score
73
ACADIA Pharmaceuticals Inc.
ACAD·Healthcare
B ★★★Hold
Current$21.23
Target$28.79
Return+35.6%
Nov 7, 2026

ACADIA's growing DAYBUE and NUPLAZID franchises, strong liquidity, and neurological pipeline provide compelling long-term growth potential, although product concentration and uncertain clinical outcomes limit near-term conviction.

Score
73
The Brink's Company
BCO·Industrials
B ★★★Hold
Current$110.25
Target$125.75
Return+14.1%
Nov 7, 2026

Brink's combines an entrenched global cash-logistics network with growing ATM and digital retail services, offering attractive cash generation, although the NCR Atleos acquisition introduces substantial financing and execution risk.

Score
73
Clear Secure, Inc.
YOU·Technology
B ★★★Hold
Current$55.81
Target$61.20
Return+9.7%
Nov 7, 2026

CLEAR combines a defensible airport identity network, accelerating revenue growth, and strong cash generation, but elevated valuation and dependence on airport partnerships constrain its margin of safety.

Score
73
Trimble Inc.
TRMB·Technology
B ★★★Hold
Current$54.11
Target$64.00
Return+18.3%
Nov 7, 2026

Trimble combines sticky industrial software, precision positioning technology, and strong free cash flow at a more attractive valuation, but slowing recurring-revenue growth and unresolved reporting-control weaknesses constrain conviction.

Score
73
Albemarle Corporation
ALB·Materials
B ★★★Hold
Current$99.25
Target$114.84
Return+15.7%
Nov 7, 2026

Albemarle offers leveraged exposure to long-term lithium demand and recovering free cash flow at a relatively modest valuation, but volatile commodity prices and capital-intensive operations limit earnings visibility.

Score
73
Corpay, Inc.
CPAY·Financials
B ★★★Hold
Current$455.16
Target$480.00
Return+5.5%
Nov 7, 2026

Corpay combines durable B2B payment relationships, strong free cash flow, and accelerating corporate payment growth, but elevated financial leverage and a historically expensive trailing valuation constrain near-term investment upside.

Score
73
The Marzetti Company
MZTI·Consumer Staples
B ★★★Hold
Current$108.50
Target$129.60
Return+19.4%
Nov 6, 2026

Marzetti combines established specialty-food brands, resilient cash generation, and recovery potential at a historically low valuation, but persistent demand weakness and manufacturing cost pressures could delay an earnings rebound.

Score
73